共查询到19条相似文献,搜索用时 171 毫秒
1.
5型磷酸二酯酶(phosphodiesterase 5,PDE5)在阴茎勃起功能中所起的作用越来越引起人们的关注。环磷酸鸟苷(cGMP)信号通路介导的一氧化氮平滑肌舒张效应是正常勃起功能的必要条件,这个信号通路的下调能引起勃起功能障碍(erectile dysfunction,ED)的许多病理状态,并导致一些慢性疾病的发生。本文回顾了伐地那非治疗ED患者的有效性和安全性。结果表明,伐地那非对于合并异常脂蛋白血症和高血压、糖尿病、抑郁症、前列腺切除术后、外伤性脊髓损伤、西地那非治疗无效、肾移植术后、慢性前列腺炎和早泄的ED患者安全有效,为这些难治性ED患者提供了一种合理的治疗选择。另外,伐地那非还能延长ED患者的勃起时间。 相似文献
2.
目的:观察伐地那非对肾阳虚、肾阴虚及肝气郁结型勃起功能障碍(ED)的临床疗效。方法:将124例ED患者按中医辨证分为肾阳虚型ED(44例)、肾阴虚型ED(41例)、肝气郁结型ED(39例),所有患者每天服用伐地那非5 mg,总疗程为8周。结果:伐地那非能显著提高各型ED患者的勃起功能问卷-5(IIEF-5)和勃起质量表(EQS)评分,且各组间比较差别有统计学意义(P<0.01);伐地那非显著提高肾阳虚和肾阴虚型ED患者性交成功百分率(P<0.01),肝气郁结型ED在治疗后性交成功百分率也有明显提高(P<0.05);伐地那非还能显著提高各型ED患者阴茎勃起硬度,3组治疗后总体有效率分别为81.82%、73.17%、43.59%。结论:伐地那非对肾阳虚和肾阴虚型ED患者疗效优于肝气郁结型ED患者。 相似文献
3.
目的评估不同剂量新型磷酸二酯酶5(PED5)抑制剂伐地那非治疗男性勃起功能障碍(ED)的有效性和安全性。方法采用随机、双盲、安慰剂平行对照、3个药物剂量(5、10和20mg)的方法,对88例ED患者进行为期12周的临床研究。结果伐地那非5mg、10mg和20mg组均能改善患者国际勃起功能指数(IIEF)中勃起功能部分的得分、患者日记中插入和保持勃起的成功率,改善程度优于安慰剂组。伐地那非20mg组对IIEF问卷中勃起功能部分得分的改善优于伐地那非5mg组。伐地那非组不良事件的发生率高于安慰剂组,但多为轻中度,且可自行缓解。结论伐地那非是治疗男性勃起功能障碍的安全、有效药物。 相似文献
4.
关于CONFIRMED研究中伐地那非与西地那非临床疗效的比较 总被引:2,自引:1,他引:1
CONFIRMED研究是完全遵循良好试验设计规范进行设计的一项研究。该研究是一项非劣性设计,主要目的是比较伐地那非与西地那非在治疗男性勃起功能障碍(ED)方面患者选择的倾向性,结果表明,总体倾向性伐地那非优于西地那非,尤其在总体满意度、性交满意度及伴侣关系满意度等方面显著优于西地那非。通过比较伐地那非与西地那非的结构,伐地那非的结构更具优势,其5型磷酸二酯酶(PDE5)选择性远远高于西地那非,这是伐地那非临床疗效优于西地那非的分子学基础。本研究提供了伐地那非优于西地那非的临床证据,进一步证实了伐地那非是对ED患者进行治疗的一线药物。 相似文献
5.
舍曲林和伐地那非治疗合并勃起功能障碍的早泄患者的临床观察 总被引:6,自引:2,他引:4
目的:评价舍曲林和伐地那非治疗合并勃起功能障碍(ED)的早泄患者的临床疗效和安全性。方法:60例诊断为合并ED的早泄患者随机分为舍曲林组和伐地那非组,每组30例。舍曲林组每天服用舍曲林50 mg,疗程2个月。伐地那非组每次性生活前服用伐地那非10~20 mg,疗程2个月。以治疗前后IIEF-5评分的改变来评价ED治疗效果,以治疗前后阴道内射精潜伏期(IELT)的变化来评价早泄治疗效果。结果:伐地那非组勃起功能改善24例,有效率为80%;而舍曲林组仅8例勃起功能改善,有效率为27%,两者差异有显著性(P<0.05)。伐地那非组早泄改善20例,有效率为67%;而舍曲林组早泄改善12例,有效率为40%,两者差异有显著性(P<0.05)。两组患者中,勃起功能改善者的早泄治疗的有效率均显著高于勃起功能无改善者。两组的不良反应均为轻度,无停药者。结论:对合并ED的早泄患者,改善患者的勃起功能是关键。 相似文献
6.
伐地那非在肾移植伴勃起功能障碍患者中应用的有效性和安全性研究 总被引:1,自引:1,他引:0
目的:评估伐地那非在肾移植后伴阴茎勃起功能障碍(ED)患者中应用的有效性和安全性。方法:选取39例血浆肌酐值<2mg/dl的肾移植伴有ED患者进行为期4周随机、双盲的伐地那非研究,实验组20例,安慰剂组19例。应用勃起功能国际指数(IIEF)进行伐地那非有效性的评估;应用血清肌酐值,肌酐清除率和血液中免疫抑制剂环孢素浓度监测值评估伐地那非的安全性。结果:应用伐地那非治疗的ED患者评分从12.6±3.4改善到26.5±2.8(P<0.01)。肾功能和环孢素浓度在伐地那非治疗前后没有改变。有4例伐地那非组患者观察到不良反应,2例出现头痛,1例出现心悸伴颜面潮红,还有1例出现消化不良。结论:本研究证实伐地那非对肾移植伴ED患者勃起功能改善有效而且安全。 相似文献
7.
伐地那非治疗糖尿病患者的勃起功能障碍 总被引:3,自引:2,他引:1
勃起功能障碍 (erectiledysfunction ,ED)在糖尿病患者中发生率要高于非糖尿病人群 ,而且更难治疗。伐地那非是一种高选择性的新型磷酸二酯酶 5抑制剂 ,是广泛ED人群的一线治疗药物。最近发表的大型临床试验表明 ,无论糖尿病合并ED的患者基线时的病情严重程度如何 ,也无论他们的血糖控制情况如何 ,伐地那非都能有效地改善其勃起功能 ,而且使用安全 ,耐受性良好 相似文献
8.
口服伐地那非治疗勃起功能障碍疗效和安全性的临床研究 总被引:1,自引:1,他引:0
目的 :评价伐地那非对男性勃起功能障碍 (ED)患者的疗效和安全性。 方法 :应用随机、双盲、安慰剂平行对照、剂量固定 (5、1 0和 2 0mg)方法 ,对 88例ED患者进行 1 2周的临床研究。 结果 :5、1 0和 2 0mg伐地那非使ED患者达到和维持勃起的临床主要和次要指标均明显高于安慰剂 (P <0 .0 1 ) ;伐地那非各剂量组不良事件发生率高于安慰剂组 ,均为轻至中度 ,呈一过性。 结论 :伐地那非是治疗各种病因导致ED的安全、有效的药物。 相似文献
9.
EDOS是一项在全欧开展,旨在评估勃起功能障碍(ED)男性患者在实际临床中接受6个月他达拉非、枸橼酸西地那非(西地那非)或盐酸伐地那非(伐地那非)治疗后健康状况的研究。研究中药物的疗效和患者满意度的评估指标为一些已经得到确认的问卷,如全球评估问卷(GAQ)、国际勃起功能指数(IIEF)、 相似文献
10.
勃起功能障碍(erectile dysfunction,ED)在糖尿病患者中发生率要高于非糖尿病人群,而且更难治疗。伐地那非是一种高选择性的新型磷酸二酯酶5抑制剂,是广泛ED人群的一线治疗药物。最近发表的大型临床试验表明,无论糖尿病合并ED的患者基线时的病情严重程度如何,也无论他们的血糖控制情况如何,伐地那非都能有效地改善其勃起功能,而且使用安全,耐受性良好。 相似文献
11.
《European Urology Supplements》2002,1(3):4-11
Epidemiological data indicate that erectile dysfunction (ED) affects over 140 million men worldwide, with the highest prevalence in men over 60 years. While the condition is often associated with coronary artery disease, hyperlipidemia, hypertension and diabetes, and may be a marker for these conditions, most men who present with ED for treatment have mild to moderate dysfunction. Treatment guidelines developed by an international, multidisciplinary panel of experts as a “process of care model for erectile dysfunction” recommend the implementation of oral agents as first-line therapy. Sublingual apomorphine SL is the first medication for the treatment of erectile dysfunction with a central mechanism of action. In clinical studies, apomorphine SL provides clinical erectogenic benefits at 2 and 3 mg doses particularly in those patients with mild to moderate ED. Apomorphine SL has the added advantages of a rapid onset of action, resulting in erection in less than half the time required by sildenafil, and a highly favorable tolerability and safety profile, especially in patients with coronary artery disease receiving nitrates. Apomorphine SL is an important addition to the armamentarium of primary care clinicians and urologists treating male erectile dysfunction, due to enhanced erectile function, speed of onset, convenience of dosing, and favorable side effect profile. Apomorphine SL 2 and 3 mg is an effective first-line treatment option for men presenting with mild to moderate ED, who have a degree of residual erectile function that is inadequate for satisfactory sexual performance. 相似文献
12.
Kloner R 《International journal of impotence research》2007,19(3):296-302
Recent analyses suggest that about 67-68% of men with hypertension have some degree of erectile dysfunction (ED). With about 25 million men in the US with hypertension, substantial numbers of hypertension-related ED exist that tend to be of a more severe nature than the general population. Men with ED are also more likely to have hypertension. Thiazide diuretic and beta-blocker therapy may contribute to ED. Phosphodiesterase-5 (PDE5) inhibitors are effective therapy in men with ED owing to hypertension who are taking antihypertensive medicines including those on multiple antihypertensive medicines. The addition of PDE5 inhibitors to usual common antihypertensive medicines (diuretics, beta blockers, calcium blockers, angiotensin converting enzyme inhibitors and angiotensin receptor blockers) results in either no or small additive reductions in blood pressure (BP) and no increase in serious clinical adverse events. There are however precautions regarding the use of PDE5 inhibitors in patients taking alpha blockers for either hypertension or benign prostatic hypertrophy, as some patients may develop orthostatic hypotension. Organic nitrates remain an absolute contraindication for PDE5 inhibitors because synergistic and symptomatic reductions in BP may occur in some patients with this drug combination. 相似文献
13.
Kloner RA Sadovsky R Johnson EG Mo D Ahuja S 《International journal of impotence research》2005,17(5):450-454
Many men with erectile dysfunction (ED) have hypertension as a comorbid condition. Recent guidelines recommend thiazide diuretics as first-line therapy for hypertension. We analyzed data from 14 randomized, double-blind, placebo-controlled trials (N=2501) to evaluate the efficacy of tadalafil 20 mg for the treatment of ED in men on thiazides. Of the 2501 patients, 163 were on concomitant thiazides (116 tadalafil/47 placebo) and 159 (98%) were reported to have hypertension. The primary efficacy measures were mean change from baseline in the international index of erectile function (IIEF) erectile function (EF) domain and the proportion of 'yes' responses to sexual encounter profile (SEP) Questions 2 and 3. The tadalafil group showed a significantly (P<0.001) greater mean baseline to endpoint improvement on all efficacy outcome measures compared to placebo-treated patients regardless of concomitant thiazide use. More importantly, the responses to tadalafil were similar regardless of concomitant thiazide use. Additionally, responses to tadalafil were comparable between thiazide and nonthiazide users regardless of baseline ED severity (P>0.05). 相似文献
14.
全面康复:勃起功能障碍治疗的新目标 总被引:1,自引:1,他引:0
5型磷酸二酯酶(PDE5)抑制剂有效改善勃起功能障碍(ED)患者的勃起功能。枸橼酸西地那非的应用范围不断扩展,肺动脉高压已成为新的适应证。临床研究发现,西地那非能改善多种血管性疾病患者的内皮功能。在ED领域的研究进展包括:动物实验发现,西地那非可以改善海绵体内皮功能,增强磷酸化内皮型一氧化氮合酶(eNOS)蛋白表达,逆转缺血或缺氧导致的海绵体内压(ICP)降低。临床研究证实,西地那非可以使50%以上ED患者阴茎勃起恢复到最充分的硬度(4级勃起);使50%以上保留神经的根治性前列腺切除术后患者勃起功能康复,自发产生足以性交的勃起;使ED患者的自尊心、自信心和性关系满意度等社会心理功能恢复正常。从勃起功能到社会心理功能的全面恢复可能成为今后ED治疗的新目标。 相似文献
15.
抗高血压药物对中老年男性高血压患者勃起功能的影响 总被引:1,自引:0,他引:1
目的 探讨不同抗高血压药物对于男性勃起功能的影响.方法 问卷调查2008年10月至2008年12月来我院就诊的已婚男性、原发性高血压患者244例,年龄40~70岁.记录服用的抗高血压药物并应用国际勃起功能指数-5(IIEF-5)评估其勃起功能.结果 244例高血压患者勃起功能正常者69例(28.28%),勃起功能障碍(ED)者175例(71.72%).其中轻度障碍者120例(49.1 8%),中度障碍者16例(6.56%),重度障碍者39例(15.98%).β受体滞剂组IIEF分值低于非β受体阻滞剂组,ED发生率高于非β受体阻滞剂组,其他药物组如血管紧张素转换酶抑制剂组、血管紧张素Ⅱ受体拮抗剂组、钙离子拮抗剂组、利尿剂组间差异均无统计学意义.结论 高血压患者中ED的发生率较高(175/244,71.72%), 服用β受体阻滞剂对患者勃起功能有不利影响,而其他药物对于勃起功能影响相似. 相似文献
16.
Perelman MA 《The Urologic clinics of North America》2011,38(2):125-139
The comorbid conditions erectile dysfunction (ED) and depression are highly prevalent in men. Multiple regression analysis to control for all other predictors of ED indicate that men with high depression scores are nearly twice as likely to report ED than nondepressed men. Depression continues to be among the most common comorbid problems in men with ED, both in the community and in clinical samples. This article reviews the current knowledge about the relationship between ED and depression, the effect of treatments for depression on ED, ways to improve screening for depression, and treatment of ED in patients with this comorbidity. 相似文献
17.
Frequency and determinants of erectile dysfunction in Italy 总被引:2,自引:0,他引:2
Parazzini F Menchini Fabris F Bortolotti A Calabrò A Chatenoud L Colli E Landoni M Lavezzari M Turchi P Sessa A Mirone V 《European urology》2000,37(1):43-49
OBJECTIVE: To analyze the prevalence and risk factors for erectile dysfunction (ED) in Italy in a cross-sectional study. METHODS: Eligible for the study were men aged 18 years or more, randomly identified by 143 general practitioners among their registered patients during the period January 1996 to February 1997. ED was defined as the impossibility to achieve and maintain an erection sufficient for satisfactory sexual performance. RESULTS: Of the 2, 010 men interviewed, 257 (12.8%) reported ED. The prevalence increased with age, from 2% in men aged 18-39 to 48% in those >70 years (tested for trend, p = 0.0001). A history of cardiopathy, diabetes, hypertension, neuropathy, thrombotic/hemorrhagic stroke, peripheral vascular disorders, pelvic/medullary injury and pelvic surgery/radiation all increased the risk of ED. The association of hypertension and diabetes tends to increase the risk of ED. In comparison with nondiabetic and nonhypertensive men, the odds ratio (OR) was 1.4 (95% confidence interval (CI), 0.7-3.2) for hypertensive men without diabetes, 4.6 (95% CI, 1.6-13.7) for diabetic men without hypertension and 8.1 (95% CI, 1.2-55.0) for men with diabetes and hypertension. In comparison with never smokers, the OR of ED was 1.7 (95% CI, 1.2-2.4) for current smokers and 1.6 (95% CI, 1.1-2.3) for ex-smokers and increased with duration of the habit. CONCLUSIONS: The study offers a quantitative estimate of the prevalence of ED and of its main risk factors in Italian men. 相似文献
18.
PURPOSE:: We examined whether men with erectile dysfunction (ED) are more likely to have hypertension than men without ED in a managed care setting. MATERIALS AND METHODS:: We used a naturalistic cohort design to compare hypertension prevalence rates in 285,436 men with ED to that in 1,584,230 men without ED from 1995 through 2001. We also used a logistic regression model to isolate the effect of ED on the likelihood of hypertension after controlling for subject age, census regions and 9 concurrent diseases. The ED and the nonED cohort came from a nationally representative, managed care claims database that covers 51 health plans and 28 million members in the United States. Finally, the prevalence rate difference between members with and without ED, and the OR of having hypertension were calculated. RESULTS:: The hypertension prevalence rate was 41.2% in men with ED and 19.2% in men without ED. After controlling for subject age, census region and 9 concurrent diseases the OR was 1.383 (p <0.0001), which implies that the odds for men with ED to have hypertension were 38.3% higher than the odds for men without ED. CONCLUSIONS:: Men with ED were more likely to have hypertension than men without ED. This evidence supports the hypothesis that ED shares common risk factors with hypertension. It also suggests that men with ED and clinicians could use ED as an alerting signal to detect and treat undiagnosed hypertension earlier. 相似文献
19.
Aging is associated with a decline in several important health factors in men, including libido. Serum testosterone concentrations also decrease with age, and many age-related clinical features are closely associated with androgen deficiency, including erectile function (ED). Approximately 70% of ED is of organic origin, with the major risk factors being diabetes mellitus, hypercholesterolemia, smoking and chronic medical illnesses. These are also established risk factors for atherosclerosis, which is the predominant predisposing factor of vasculogenic ED. The introduction of phosphodiasterase-5 (PDE-5) inhibitors for the treatment of ED made a significant impact both in terms of clinical efficacy, and increasing the awareness of the condition. In spite of this, some patients fail to respond to PDE-5 inhibitors alone. Both animal and clinical studies indicate that testosterone therapy improves both erectile function and the response to PDE-5 inhibitors in patients with ED and hypogonadism. Indeed, interventional studies demonstrate that testosterone replacement therapy improves erectile function in hypogonadal men who have previously failed to respond to PDE-5 inhibitors alone. Furthermore, it has been demonstrated that the full therapeutic potential of PDE5 inhibitors will only become manifest in a eugonadal state. Recent studies have demonstrated a close relationship between testosterone and ED and suggest that testosterone therapy may be a valuable option for an increasing number of affected men. European guidelines recommend that all men presenting with ED should have their testosterone concentrations measured. 相似文献